Company is growing. I wouldn’t say rapidly, but it is growing. It is CFP and has been for a while. These are in publicly released financials.
Big question is how long will it take for Elite to get back to CFP and growth after Lannett canceled the partnership and they have to rebuild sales structure? How much cash will they burn? Do they slow down R&D until sales and cash flow stabilize?
R&D has only had only one solid win in Nasrat’s tenure, Adderall IR, through partnership with Sungen. Throwing darts would have had a better R&D outcome. Adderall ER has the potential, but Lannett couldn’t sell it.
Let’s see what Kirko can do. Getting back to CFP is a solid start, but not expecting it for Q1 reporting released in July as they were building inventory.
News 
Market Data 
Discover 
